Nevertheless, the two published studies provided independent evidence supporting our hypothesis that TF is expressed by macrophages, B cells, Ki-67 positive synoviocytes and angiogenic VECs in RA and targeting TF represents a novel therapeutic approach for immunotherapy of RA. The gene discussed is TF; the disease is rheumatoid arthritis.